Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
MOSAIC
About the Trial
The Multicenter International Study of Oxaliplatin 5 Fluorouracil Leucovorin in the Adjuvant Treatment of Colon Cancer randomized 2,246 stage II and III colon cancer patients to FOLFOX or standard 5 FU leucovorin. FOLFOX improved 3 year disease free survival from 72.9 to 78.2 percent, later translating into overall survival gain in stage III. Oxaliplatin, a platinum analog with distinctive neurotoxicity, became the third drug in colorectal therapy. Cure rates for stage III colon cancer rose by roughly 5 absolute percent. MOSAIC set the adjuvant backbone that the IDEA collaboration later refined by studying treatment duration, and it remains foundational in colon cancer management.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...